FATE THERAPEUTICS INC Recognition of Deferred Revenue
FATE THERAPEUTICS INC (FATE) reported Recognition of Deferred Revenue of -$7.91 million for the 9-month period ending 2015-09-30, per its 10-Q filed 2015-11-03.
Discontinued › Income Statement › Other Income
us-gaap:RecognitionOfDeferredRevenue · last filed 2015-11-03
- FATE THERAPEUTICS INC recognition of deferred revenue for the quarter ending 2015-09-30 was $180.00K.
- FATE THERAPEUTICS INC recognition of deferred revenue for the quarter ending 2013-12-31 was $0.00, a 100.00% decline year-over-year.
- FATE THERAPEUTICS INC recognition of deferred revenue for the quarter ending 2013-09-30 was $21.00K.
- FATE THERAPEUTICS INC recognition of deferred revenue for the quarter ending 2013-06-30 was $21.00K.
- FATE THERAPEUTICS INC recognition of deferred revenue for fiscal 2013 was $63.00K, a 24.10% decline from fiscal 2012.
- FATE THERAPEUTICS INC recognition of deferred revenue for fiscal 2012 was $83.00K, a 87.15% decline from fiscal 2011.
- FATE THERAPEUTICS INC recognition of deferred revenue for fiscal 2011 was $646.00K.
| Period end | Recognition of Deferred Revenue 3 month | Recognition of Deferred Revenue 6 month | Recognition of Deferred Revenue 9 month | Recognition of Deferred Revenue 12 month |
|---|---|---|---|---|
| 2015-09-30 | $180.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-03 | -$7.91M 10-Q · filed 2015-11-03 | ||
| 2015-06-30 | -$8.09M 10-Q · filed 2015-08-05 | |||
| 2013-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-12 | $21.00K derived: sum of 2 quarters · filed 2015-03-12 | $42.00K derived: sum of 3 quarters · filed 2015-03-12 | $63.00K 10-K · filed 2015-03-12 |
| 2013-09-30 | $21.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-12 | $42.00K derived: sum of 2 quarters · filed 2014-11-12 | $63.00K 10-Q · filed 2014-11-12 | $83.00K derived: sum of 4 quarters · filed 2015-03-12 |
| 2013-06-30 | $21.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-12 | $42.00K 10-Q · filed 2014-08-12 | $62.00K derived: sum of 3 quarters · filed 2015-03-12 | |
| 2013-03-31 | $21.00K 10-Q · filed 2014-05-13 | $41.00K derived: sum of 2 quarters · filed 2015-03-12 | ||
| 2012-12-31 | $20.00K derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-12 | $83.00K 10-K · filed 2015-03-12 | ||
| 2012-09-30 | $63.00K 10-Q · filed 2013-11-13 | |||
| 2011-12-31 | $646.00K 10-K · filed 2014-03-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |